by ManiOctober 27, 2014, 11:30 am
Sarepta Therapeutics Inc (NASDAQ:SRPT) said Monday the U.S. Food and Drug Administration asked the biotech company to submit additional data for its planned New Drug Application for the approval of its drug eteplirsen.
Read more